BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22732877)

  • 1. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus.
    Gupta N; Gaddam S; Wani SB; Bansal A; Rastogi A; Sharma P
    Gastrointest Endosc; 2012 Sep; 76(3):531-8. PubMed ID: 22732877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy.
    Borovicka J; Fischer J; Neuweiler J; Netzer P; Gschossmann J; Ehmann T; Bauerfeind P; Dorta G; Zürcher U; Binek J; Meyenberger C
    Endoscopy; 2006 Sep; 38(9):867-72. PubMed ID: 16981102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
    Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
    Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
    Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
    Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience.
    Wang VS; Hornick JL; Sepulveda JA; Mauer R; Poneros JM
    Gastrointest Endosc; 2009 Apr; 69(4):777-83. PubMed ID: 19136106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma.
    Larghi A; Lightdale CJ; Ross AS; Fedi P; Hart J; Rotterdam H; Noffsinger A; Memeo L; Bhagat G; Waxman I
    Endoscopy; 2007 Dec; 39(12):1086-91. PubMed ID: 17701854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of lesions in dysplastic Barrett's esophagus by community and expert endoscopists.
    Schölvinck DW; van der Meulen K; Bergman JJGHM; Weusten BLAM
    Endoscopy; 2017 Feb; 49(2):113-120. PubMed ID: 27855466
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
    Conio M; Blanchi S; Lapertosa G; Ferraris R; Sablich R; Marchi S; D'Onofrio V; Lacchin T; Iaquinto G; Missale G; Ravelli P; Cestari R; Benedetti G; Macrì G; Fiocca R; Munizzi F; Filiberti R
    Am J Gastroenterol; 2003 Sep; 98(9):1931-9. PubMed ID: 14499768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Location, location, location: does early cancer in Barrett's esophagus have a preference?
    Enestvedt BK; Lugo R; Guarner-Argente C; Shah P; Falk GW; Furth E; Ginsberg GG
    Gastrointest Endosc; 2013 Sep; 78(3):462-7. PubMed ID: 23622975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circumferential location predicts the risk of high-grade dysplasia and early adenocarcinoma in short-segment Barrett's esophagus.
    Kariyawasam VC; Bourke MJ; Hourigan LF; Lim G; Moss A; Williams SJ; Fanning SB; Chung AM; Byth K
    Gastrointest Endosc; 2012 May; 75(5):938-44. PubMed ID: 22381529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
    Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
    Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.